FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604090970> ?p ?o ?g. }

• W2604090970 endingPage "18500" @default.
• W2604090970 startingPage "18500" @default.
• W2604090970 abstract "18500 Background: Pegylated liposomal doxorubicin (PLD, DOXIL) was developed to decrease the cardiotoxicity risk associated with conventional doxorubicin. However, hand-foot syndrome (HFS) and mucositis are more common with PLD 50 mg/m 2 every 4 weeks (q4w) than with 20 mg/m 2 q3w (all grades: HFS, 37.4% vs 3.4%; mucositis, 37.4% vs 6.8%). A lower dose intensity of PLD 10 mg/m 2 /wk (40 mg/m 2 vs 50 mg/m 2 q4w) was reported to have similar efficacy in ovarian cancer but reduced incidence of HFS and mucositis. This study evaluated the tolerability of the lower dose intensity using a 20 mg/m 2 q2w regimen in patients (pts) with Kaposi’s sarcoma (KS), hematologic tumors, and solid tumors. Methods: This retrospective chart review included pts who received PLD as a component of care at a single community oncology clinic between January 2000 and December 2004. Demographics, PLD dosing, and tolerability were recorded. Data were censored for pts with an initial PLD dose other than 20 mg/m 2 q2w. Results: Of the 157 pts given PLD, 79 received an initial dose of 20 mg/m 2 q2w. Tumors included 47 KS, 8 hematologic (3 multiple myeloma, 4 lymphoma, 1 leukemia), and 24 solid (8 breast, 5 gynecologic, 3 colorectal, 2 liver, 2 lung, 2 sarcoma, 1 prostate, 1 thyroid). Median cumulative dose was 220 mg/m 2 (range, 20–2320 mg/m 2 ); 34 pts (31 KS, 0 hematologic, 3 solid) received >300 mg/m 2 and 14 pts (13 KS, 1 solid) received >550 mg/m 2 . No signs (eg, decreased LVEF) or treatment-related symptoms of cardiotoxicity (eg, shortness of breath) were reported. Incidence of HFS and mucositis are reported in the Table . One HFS and 1 mucositis led to PLD discontinuation. Conclusions: Regardless of tumor type, PLD 20 mg/m 2 q2w appears well tolerated. No cardiotoxicity was observed, even at cumulative doses >550 mg/m 2 . Rates of HFS and mucositis were lower than reported previously with a 50 mg/m 2 q4w schedule. Prospective studies in larger populations are warranted to further examine the efficacy of the PLD 20 mg/m 2 q2w schedule and dose intensity. [Table: see text] [Table: see text]" @default.
• W2604090970 created "2017-04-07" @default.
• W2604090970 creator A5006285770 @default.
• W2604090970 creator A5012507181 @default.
• W2604090970 creator A5023047673 @default.
• W2604090970 creator A5089966140 @default.
• W2604090970 date "2006-06-20" @default.
• W2604090970 modified "2023-09-24" @default.
• W2604090970 title "Tolerability of pegylated liposomal doxorubicin 20 mg/m2 every 2 weeks in the management of solid or hematologic malignancies" @default.
• W2604090970 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.18500" @default.
• W2604090970 hasPublicationYear "2006" @default.
• W2604090970 type Work @default.
• W2604090970 sameAs 2604090970 @default.
• W2604090970 citedByCount "0" @default.
• W2604090970 crossrefType "journal-article" @default.
• W2604090970 hasAuthorship W2604090970A5006285770 @default.
• W2604090970 hasAuthorship W2604090970A5012507181 @default.
• W2604090970 hasAuthorship W2604090970A5023047673 @default.
• W2604090970 hasAuthorship W2604090970A5089966140 @default.
• W2604090970 hasConcept C126322002 @default.
• W2604090970 hasConcept C141071460 @default.
• W2604090970 hasConcept C197934379 @default.
• W2604090970 hasConcept C2776694085 @default.
• W2604090970 hasConcept C2778375690 @default.
• W2604090970 hasConcept C2778496288 @default.
• W2604090970 hasConcept C2779051857 @default.
• W2604090970 hasConcept C2781413609 @default.
• W2604090970 hasConcept C71924100 @default.
• W2604090970 hasConcept C90924648 @default.
• W2604090970 hasConceptScore W2604090970C126322002 @default.
• W2604090970 hasConceptScore W2604090970C141071460 @default.
• W2604090970 hasConceptScore W2604090970C197934379 @default.
• W2604090970 hasConceptScore W2604090970C2776694085 @default.
• W2604090970 hasConceptScore W2604090970C2778375690 @default.
• W2604090970 hasConceptScore W2604090970C2778496288 @default.
• W2604090970 hasConceptScore W2604090970C2779051857 @default.
• W2604090970 hasConceptScore W2604090970C2781413609 @default.
• W2604090970 hasConceptScore W2604090970C71924100 @default.
• W2604090970 hasConceptScore W2604090970C90924648 @default.
• W2604090970 hasIssue "18_suppl" @default.
• W2604090970 hasLocation W26040909701 @default.
• W2604090970 hasOpenAccess W2604090970 @default.
• W2604090970 hasPrimaryLocation W26040909701 @default.
• W2604090970 hasRelatedWork W112819031 @default.
• W2604090970 hasRelatedWork W1541193958 @default.
• W2604090970 hasRelatedWork W1968036257 @default.
• W2604090970 hasRelatedWork W2007986200 @default.
• W2604090970 hasRelatedWork W2020073008 @default.
• W2604090970 hasRelatedWork W2171389860 @default.
• W2604090970 hasRelatedWork W2281121233 @default.
• W2604090970 hasRelatedWork W2465078823 @default.
• W2604090970 hasRelatedWork W2737644370 @default.
• W2604090970 hasRelatedWork W2896565415 @default.
• W2604090970 hasVolume "24" @default.
• W2604090970 isParatext "false" @default.
• W2604090970 isRetracted "false" @default.
• W2604090970 magId "2604090970" @default.
• W2604090970 workType "article" @default.